Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Misses on EPS, Stock Down 5.36%

Supernus Pharmaceuticals reported an EPS of $0.02, which met expectations, but there was no revenue reported. The stock reacted negatively, dropping 5.36%, indicating investor concerns despite the EPS result. The lack of guidance and additional commentary may have contributed to the stock's decline.